BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hamilton SR. Targeted therapy of cancer: new roles for pathologists in colorectal cancer. Mod Pathol. 2008;21 Suppl 2:S23-S30. [PMID: 18437170 DOI: 10.1038/modpathol.2008.14] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Nosho K, Shima K, Irahara N, Kure S, Firestein R, Baba Y, Toyoda S, Chen L, Hazra A, Giovannucci EL. SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol. 2009;22:922-932. [PMID: 19430421 DOI: 10.1038/modpathol.2009.49] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 5.8] [Reference Citation Analysis]
2 Hino-Shishikura A, Suzuki A, Minamimoto R, Shizukuishi K, Oka T, Tateishi U, Sugae S, Ichikawa Y, Horiuchi C, Inoue T. Biodistribution and radiation dosimetry of [¹⁸F]-5-fluorouracil. Appl Radiat Isot 2013;75:11-7. [PMID: 23416442 DOI: 10.1016/j.apradiso.2013.01.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
3 Komori S, Osada S, Tomita H, Nishio K, Kumazawa I, Tachibana S, Tsuchiya J, Yoshida K. Predictive value of orotate phosphoribosyltransferase in colorectal cancer patients receiving 5-FU-based chemotherapy. Mol Clin Oncol 2013;1:453-60. [PMID: 24649191 DOI: 10.3892/mco.2013.71] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
4 Ross JS, Torres-Mora J, Wagle N, Jennings TA, Jones DM. Biomarker-based prediction of response to therapy for colorectal cancer: current perspective. Am J Clin Pathol 2010;134:478-90. [PMID: 20716806 DOI: 10.1309/AJCP2Y8KTDPOAORH] [Cited by in Crossref: 48] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
5 Wang L, Chen X, Li W, Sheng Z. Antiepidermal growth factor receptor monoclonal antibody improves survival outcomes in the treatment of patients with metastatic colorectal cancer. Anticancer Drugs 2012;23:155-60. [PMID: 21955998 DOI: 10.1097/CAD.0b013e32834c3256] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27:663-671. [PMID: 19114683 DOI: 10.1200/jco.2008.20.8397] [Cited by in Crossref: 1166] [Cited by in F6Publishing: 527] [Article Influence: 89.7] [Reference Citation Analysis]
7 Weichert W, Schewe C, Lehmann A, Sers C, Denkert C, Budczies J, Stenzinger A, Joos H, Landt O, Heiser V, Röcken C, Dietel M. KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn 2010;12:35-42. [PMID: 20007841 DOI: 10.2353/jmoldx.2010.090079] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 6.3] [Reference Citation Analysis]
8 An Y, Zhou Y, Ren G, Tian Q, Lu Y, Li H, Li K, Su T, Xu B, Chen S. Elevated expression of MGb2-Ag/TRAK1 is correlated with poor prognosis in patients with colorectal cancer. Int J Colorectal Dis. 2011;26:1397-1404. [PMID: 21573901 DOI: 10.1007/s00384-011-1237-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
9 Ross JS. Biomarker-based selection of therapy for colorectal cancer. Biomark Med 2011;5:319-32. [PMID: 21657841 DOI: 10.2217/bmm.11.38] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
10 Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunology--analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol. 2011;8:711-719. [PMID: 21826083 DOI: 10.1038/nrclinonc.2011.122] [Cited by in Crossref: 183] [Cited by in F6Publishing: 188] [Article Influence: 18.3] [Reference Citation Analysis]
11 Mooberry LK, Nair M, Paranjape S, McConathy WJ, Lacko AG. Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J Drug Target. 2010;18:53-58. [PMID: 19637935 DOI: 10.3109/10611860903156419] [Cited by in Crossref: 84] [Cited by in F6Publishing: 94] [Article Influence: 7.6] [Reference Citation Analysis]
12 Vlajnic T, Andreozzi MC, Schneider S, Tornillo L, Karamitopoulou E, Lugli A, Ruiz C, Zlobec I, Terracciano L. VEGFA gene locus (6p12) amplification identifies a small but highly aggressive subgroup of colorectal cancer [corrected] patients. Mod Pathol 2011;24:1404-12. [PMID: 21743435 DOI: 10.1038/modpathol.2011.96] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
13 Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut. 2011;60:397-411. [PMID: 21036793 DOI: 10.1136/gut.2010.217182] [Cited by in Crossref: 379] [Cited by in F6Publishing: 381] [Article Influence: 34.5] [Reference Citation Analysis]
14 Chen J, Luo X, Xie G, Chen K, Jiang H, Pan F, Li J, Ruan Z, Pang X, Liang H. Functional Analysis of SNPs in the ERCC5 Promoter in Advanced Colorectal Cancer Patients Treated With Oxaliplatin-Based Chemotherapy. Medicine (Baltimore). 2016;95:e3652. [PMID: 27175691 DOI: 10.1097/md.0000000000003652] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
15 Nakata K, Nagai E, Ohuchida K, Aishima S, Hayashi A, Miyasaka Y, Yu J, Mizumoto K, Tanaka M, Tsuneyoshi M. REG4 is associated with carcinogenesis in the 'intestinal' pathway of intraductal papillary mucinous neoplasms. Mod Pathol. 2009;22:460-468. [PMID: 19136934 DOI: 10.1038/modpathol.2008.205] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
16 Xie FW, Peng YH, Chen X, Chen X, Li J, Yu ZY, Wang WW, Ouyang XN. Regulation and expression of aberrant methylation on irinotecan metabolic genes CES2, UGT1A1 and GUSB in the in-vitro cultured colorectal cancer cells. Biomed Pharmacother 2014;68:31-7. [PMID: 24439671 DOI: 10.1016/j.biopha.2013.06.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
17 Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB 3rd, Goldberg RM, Bertagnolli MM, Fuchs CS. Cancer and Leukemia Group B, North Central Cancer Treatment Group, Canadian Cancer Society Research Institute, Southwest Oncology Group. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res. 2009;15:7322-7329. [PMID: 19934290 DOI: 10.1158/1078-0432.ccr-09-1570] [Cited by in Crossref: 141] [Cited by in F6Publishing: 85] [Article Influence: 11.8] [Reference Citation Analysis]
18 Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst. 2010;102:365-367. [PMID: 20208016 DOI: 10.1093/jnci/djq031] [Cited by in Crossref: 126] [Cited by in F6Publishing: 137] [Article Influence: 11.5] [Reference Citation Analysis]
19 Gao C. Molecular pathological epidemiology in diabetes mellitus and risk of hepatocellular carcinoma. World J Hepatol 2016; 8(27): 1119-1127 [PMID: 27721917 DOI: 10.4254/wjh.v8.i27.1119] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
20 Tang JC, Feng YL, Liang X, Cai XJ. Autophagy in 5-Fluorouracil Therapy in Gastrointestinal Cancer: Trends and Challenges. Chin Med J (Engl). 2016;129:456-463. [PMID: 26879020 DOI: 10.4103/0366-6999.176069] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
21 Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, van Ballegooijen M, Goede SL, Ries LA. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544-573. [PMID: 19998273 DOI: 10.1002/cncr.24760] [Cited by in Crossref: 1205] [Cited by in F6Publishing: 1223] [Article Influence: 109.5] [Reference Citation Analysis]
22 Meteoglu I, Erdogdu IH, Tuncyurek P, Coskun A, Culhaci N, Erkus M, Barutca S. Nuclear Factor Kappa B, Matrix Metalloproteinase-1, p53, and Ki-67 Expressions in the Primary Tumors and the Lymph Node Metastases of Colorectal Cancer Cases. Gastroenterol Res Pract 2015;2015:945392. [PMID: 25945089 DOI: 10.1155/2015/945392] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
23 Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544-573. [PMID: 19998273 DOI: 10.1002/cncr.24760]] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Liu J, Zuo X, Li C, Yu T, Gu X, Zhou C, Li Z, Goetz M, Kiesslich R, Li Y. In vivo molecular imaging of epidermal growth factor receptor in patients with colorectal neoplasia using confocal laser endomicroscopy. Cancer Lett. 2013;330:200-207. [PMID: 23220286 DOI: 10.1016/j.canlet.2012.11.044] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 4.7] [Reference Citation Analysis]
25 Glory MD, Thiruvengadam D. Potential chemopreventive role of chrysin against N-nitrosodiethylamine-induced hepatocellular carcinoma in rats. Biomedicine & Preventive Nutrition 2012;2:106-12. [DOI: 10.1016/j.bionut.2011.06.022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
26 Cervera P, Fléjou J. Changing Pathology with Changing Drugs: Tumors of the Gastrointestinal Tract. Pathobiology 2011;78:76-89. [DOI: 10.1159/000315535] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
27 刘宝瑞, 王婷婷, 钱晓萍. 原发性肝癌分子靶向治疗研究进展. 世界华人消化杂志 2009; 17(10): 993-997 [DOI: 10.11569/wcjd.v17.i10.993] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
28 Halper J. Growth factors as active participants in carcinogenesis: a perspective. Vet Pathol 2010;47:77-97. [PMID: 20080487 DOI: 10.1177/0300985809352981] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
29 Yamaguchi NH, Mayer IA, Malzyner A, de Andrade CJ, Murad AM, Del Giglio A, Alves V. Gefitinib and celecoxib in advanced metastatic gastrointestinal tumors: a pilot feasibility study. J Gastrointest Oncol 2014;5:57-66. [PMID: 24490043 DOI: 10.3978/j.issn.2078-6891.2013.056] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
30 Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn. 2012;12:621-628. [PMID: 22845482 DOI: 10.1586/erm.12.46] [Cited by in Crossref: 111] [Cited by in F6Publishing: 107] [Article Influence: 12.3] [Reference Citation Analysis]